Skip to Content
Last Updated: 03/28/2017

2017 American Association for Cancer Research (AACR) Annual Meeting

Schedule of DCTD Presentations

Several members of DCTD's staff will present information at the AACR Annual Meeting in Washington, DC between April 1-5, 2017. External Link

Oral Presentations

Time Title Presenter Location
Saturday, April 1
8:30 - 8:50 AM Utility of Patient-derived Xenograft Models to Mirror Precision Oncology Clinical Trials External Link James H. Doroshow, MD Director, DCTD Room 151, Level 1, Washington Convention Center
8:30 - 8:50 AM Clinical Trials Design Workshop - Part 1: Clinical Trials for Targeted Therapies External Link Jeffrey Moscow, MD, Cancer Therapy Evaluation Program Room 145, Level 1, Washington Convention Center
9:00 - 9:20 AM Pharmacodynamic Modeling to Predict Biologically Effective Drug Dosing External Link Ralph E. Parchment, PhD, Office of the Director Room 151, Level 1, Washington Convention Center
Sunday, April 2
2:00 - 4:00 PM Women in Cancer Research Council Meet and Greet External Link S. Percy Ivy, MD, Cancer Therapy Evaluation Program AACRcentral (Booth 1125), WICR Resource Center, Lower Level, Washington Convention Center
Monday, April 3
1:00 - 1:45 PM NCI Cancer Imaging Program Informatics Integration External Link Janet F. Eary, MD, Cancer Imaging Program Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
Tuesday, April 4
7:00 - 8:00 AM Utilizing "Normal" Genomic Data from the GTEx Project in Cancer Research External Link Helen Moore, PhD, and Abhi Rao, PhD, Cancer Diagnosis Program Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
10:30 AM - 12:30 PM Funding Opportunities for Cancer Research at Multiple National Institutes of Health (NIH) Institutes and Centers with NIH Experts External Link Julia T. Arnold, PhD, Translational Research Program Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
12:30 - 2:30 PM Technology Transfer and Intellectual Property: Career Opportunities for Researchers External Link Jason V. Cristofaro, JD, PhD, Office of the Director Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC
Wednesday, April 5
10:30 AM - 12:00 PM The NCI Best Practices for Biospecimen Resources: 2016 revised recommendations External Link Abhi Rao, PhD, Cancer Diagnosis Program Room 143, Level 1, Washington Convention Center
11:15 - 11:40 AM Tumor Models as Novel Diagnostics: Finding Drugs that Work External Link James H. Doroshow, MD, Director, DCTD Room 202, Level 2, Washington Convention Center

Poster Presentations

Time Title Location
Sunday, April 2
1:00 PM - 5:00 PM Comparison of the response of the NCI60 NSCLC panel with the response of patient-derived NSCLC lines to approved and investigational agents External Link Section 15; Abstract 348/4
1:00 PM - 5:00 PM A clinically validated multiplex immunofluorescence assay for the quantitative assessment of changes in EMT phenotypes in FFPE tumor tissues in response to cancer therapeutics External Link Section 40; Abstract 845/4
1:00 PM - 5:00 PM Biospecimen and data resources for cancer research from NCI's BPV program External Link Section 16; Abstract 376/2
Monday, April 3
8:00 AM - 12:00 PM Longitudinal expression response of glycosylation related genes, regulators, and targets in cancer cell lines treated with eleven anti-tumor agents External Link Section 24; Abstract 1557/6
8:00 AM - 12:00 PM The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high risk acute lymphoblastic leukemia External Link Section 42; Abstract 1942/14
1:00 - 5:00 PM Analysis of APOBEC3A and APOBEC3B mutational signatures using next-generation sequencing data from cancer cell lines External Link Section 24; Abstract 2590/9
Tuesday, April 4
8:00 AM - 12:00 PM The National Cancer Institute's patient-derived models repository (PDMR) External Link Section 37; Abstract 3840/6
8:00 AM - 12:00 PM A clinical pharmacodynamic biomarker assay that distinguishes potentially repairable, cytotoxic drug-induced DNA double strand breaks (DSBs) from DSBs associated with apoptotic cell death External Link Section 2; Abstract 3072/10
1:00 - 5:00 PM Effects of epigenetic agents on methylation of DNA in vitro and in vivo, as measured with stable isotopically labeled methionine External Link Section 15; Abstract 4351/7
1:00 - 5:00 PM Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations External Link Section 29; Abstract 4678/9
1:00 - 5:00 PM Establishing a platform for the generation of organoids from diverse tumor types as part of the NCI patient-derived models (PDM) initiative External Link Section 39; Abstract 4827/17
1:00 - 5:00 PM Small cell lung carcinoma (SCLC) cell line screen of standard of care (etoposide/carboplatin) plus a third agent External Link Section 39; Abstract 4831/21
Wednesday, April 5
8:00 AM - 12:00 PM Disruption of DNA methyltransferase (DNMT) 1 confers resistance to DNMT inhibitors in human colorectal cancer cells External Link Section 2; Abstract 5081/26

Meet-the-Expert Presentations

NCI Exhibit Booth # 1407

Time Topic Presenter
Sunday, April 2
3:00 - 3:15 PM Publically Available Biospecimen Resources Supported by the Cancer Diagnosis Program Rodrigo Chuaqui, MD, Irina Lubensky, MD, Joanne Demchok, MS, Cancer Diagnosis Program
3:15 - 3:30 PM Newly Revised NCI Best Practices for Biospecimen Resources Helen Moore, PhD, Cancer Diagnosis Program, Rihab Yassin, PhD, Division of Cancer Biology
Monday, April 3
1:15 - 1:45 PM Everything You Wanted to Know about the NCI-Pediatric MATCH Trial Nita Seibel, MD, Cancer Therapy Evaluation Program
3:30 - 4:00 PM The NCI Formulary: A Cancer Moonshot Initiative Jason Cristofaro, JD, PhD, Office of the Director
4:15 - 4:30 PM Patient-derived Xenograft Model Repository Yvonne Evrard, PhD, Developmental Therapeutics Program
4:30 - 4:45 PM Small Cell Lung Cancer Carcinoma Cell Line Screen of Etoposide/Carboplatin Plus a Third Agent Beverly Teicher, PhD, Developmental Therapeutics Program
Tuesday, April 4
2:00 - 2:15 PM Cancer Biomarker Assay Development & Funding Opportunities: A Cancer Diagnosis Program Initiative Aniruddha Ganguly, PhD, Cancer Diagnosis Program
2:15 - 2:30 PM NCI Pharmacodynamics Biomarker Program Katherine Ferry-Galow, PhD, Pharmacodynamic Assay, Development and Implementation Section
2:45 - 3:00 PM Translational Research at the National Cancer Institute: Specialized Programs of Research Excellence (SPOREs) Igor Kuzmin, PhD, Translational Research Program
3:00 - 3:15 PM NCI Cancer Complementary and Alternative Medicine Programs Libin Jia, MD, Office of Cancer Complementary and Alternative Medicine

DCTD Kiosk Activity: NCI Exhibit Booth # 1407

DCTD staff will interact with prospective and present grantees, provide program overview, distribute program information and funding opportunities, and provide guidance to prepare grant applications.

Time DCTD Staff
Sunday, April 2
1:00 - 3:00 PM Aniruddha Ganguly, PhD, Cancer Diagnosis Program
3:00 - 5:00 PM Katherine Ferry-Galow, PhD, Pharmacodynamic Assay, Development and Implementation Section
Monday, April 3
9:00 - 11:00 AM Sherry Ansher, PhD, Cancer Therapy Evaluation Program
11:00 AM - 1:00 PM Beverly Teicher, PhD, Developmental Therapeutics Program
1:00 - 3:00 PM Julia Arnold, PhD, Translational Research Program
Yvonne Evrard, PhD, Developmental Therapeutics Program
3:00 - 5:00 PM Steve Nothwehr, PhD, Translational Research Program
Tuesday, April 4
9:00 - 11:00 AM Abhi Rao, PhD, Cancer Diagnosis Program
Ping Guan, PhD, Cancer Diagnosis Program
11:00 AM - 1:00 PM Igor Kuzmin, PhD, Translational Research Program
1:00 - 3:00 PM Vikram Devgan, PhD, MBA, Cancer Therapy Evaluation Program
3:00 - 5:00 PM Magdalena Thurin, PhD, Cancer Diagnosis Program
Wednesday, April 5
9:00 - 10:30 AM Nina Lukinova, PhD, Cancer Diagnosis Program
10:30 AM - 12:00 PM Aniruddha Ganguly, PhD, Cancer Diagnosis Program